Background: The role of hormones in focal nodular hyperplasia (FNH) has been investigated with conflicting results.
Introduction
Focal nodular hyperplasia (FNH) is the most common solid benign liver tumour and is composed of a proliferation of hepatocytes around a central stellate scar. Histologically, FNH resembles focal cirrhosis. 1 It is a polyclonal, hyperplastic response to locally disturbed blood flow and thus differs from hepatic adenomas, which are monoclonal tumours. 2, 3 A study by Paradis et al. 2 showed X-chromosome inactivation occurs randomly in a polyclonal tumour and non-randomly in a monoclonal tumour. In all of the 15 FNH studied by these authors, X-chromosome inactivation was random. By contrast, six of seven hepatic adenomas and two hepatocellular carcinomas showed non-random patterns of X-chromosome inactivation consistent with monoclonal tumours. 2 The liver is a hormone-sensitive organ and expresses both oestrogen and androgen receptors. Sex hormones have been implicated as drivers in tumour formation. Longterm use of oral contraceptives (OCs) has been shown to induce not only adenomas, but also FNH. 4 Baum et al. 5 described the association between OC pills (OCPs) and hepatic adenomas in 1973. Liver tumours were relatively rare until the introduction of OCs in the 1960s. 6 Edmonson and HPB incidence of hepatic adenoma decreased after the introduction of modern lower-dose OCPs. 4 The role of hormones in FNH is supported by its high female predominance, younger age of onset, and high prevalence amongst individuals using OCPs (50-75% of patients with FNH use OCPs). 4, 8 Although several reports recommend the cessation of OCPs in FNH, [8] [9] [10] there are few data to support this recommendation other than the hypothesis that OCs act to accelerate already established tumours. 3 However, such recommendations are inconsistent with other reports suggesting that low-dose OCs can be maintained with FNH given that size changes during follow-up are rare and do not relate to OC use and that pregnancy is not associated with FNH changes.
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Hormone receptor immunohistochemical status has been assessed in hepatic adenomas and hepatocellular carcinomas, but less so in FNH. The predominance of FNH in females suggests a hormonal pathophysiological process may play a role in its pathogenesis; however, this has not been clearly proven. Porter et al. 12 found that nuclear oestrogen receptors were found in much greater amounts in FNH and adenoma compared with the surrounding liver parenchyma, which suggests the increased sensitivity of these tumours compared with surrounding normal liver. Kubota et al. 13 found that neither tumour expressed oestrogen or progesterone receptors in a study of two patients with enlarging FNH and a history of OCP use. Masood et al. 14 found no oestrogen receptors in five patients with FNH, one of whom was male. However, variable staining techniques may account for differences in study results. The aim of this study was to evaluate oestrogen and progesterone receptor expression in resected or biopsied FNH and surrounding normal liver tissue that was considered to represent control tissue.
Materials and methods
The study was approved by the institutional ethics committees at the Royal Adelaide Hospital and Flinders Medical Centre. Consecutive patients submitted to resection or core biopsy of FNH from 2001 to 2013 at either of these academic tertiary centres were asked to give consent and were recruited for the study.
Resected or biopsied FNH tissue and available surrounding normal tissue (controls) was stained immunohistochemically for oestrogen and progesterone hormone receptor status using the Ventana BenchMark ULTRA immunostainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) and the confirm rabbit SP1 clone monoclonal antibody for the oestrogen receptor and the confirm rabbit SP1 clone for the progesterone receptor. Slides were evaluated by two pathologists working independently. Receptor expression was graded according to the proportion score (PS) and intensity score (IS). The PS represents the percentage of nuclei staining for oestrogen and progesterone receptors according to the following categories: 0%; <1%; 1-10%; 11-33%; 34-66%, and >67%. The IS represents receptor staining intensity and is categorized as none, weak, intermediate or strong.
Results
Of 13 patients (median age: 39 years; range: 26-47 years) with FNH, 11 underwent resection of the lesion and two submitted to biopsy (Table 1) . Resections were undertaken either for symptom control or because atypical imaging characteristics had suggested adenoma. Two patients underwent biopsy of a liver lesion when imaging features were suspicious but not equivocal for FNH. The median diameter of the 11 resected lesions was 18 mm (range: 8-95 mm).
Oestrogen receptor expression in FNH
Twelve of the 13 patients demonstrated labelling with the oestrogen receptor antibody. The intensity of oestrogen receptor expression is recorded in Table 1 . Both core biopsy specimens showed the highest IS and nuclear oestrogen receptor staining.
Oestrogen receptor expression in normal surrounding liver Surrounding normal liver was available for the assessment of oestrogen receptor expression in control material in nine patients. The proportion of nuclear staining was similar to that in FNH tissue in seven of the nine patients.
Progesterone receptor expression in FNH Eleven of the 13 FNH patients showed no progesterone receptor expression in FNH specimens.
Progesterone receptor expression in normal surrounding liver
Only one of the nine available control samples demonstrated progesterone receptor expression. The FNH tissue from this patient showed no progesterone receptor expression.
Discussion
In this study, the majority of patients with resected or biopsied FNH demonstrated oestrogen receptor expression. This was also present in control liver tissue in all patients in whom control tissue was available. The proportions of nuclear oestrogen receptor staining were similar in both FNH and normal liver tissue. Only two of nine patients had differential oestrogen receptor expression between the surrounding normal liver and FNH tissue. Progesterone receptor expression was, however, negligible.
The samples showing the strongest nuclear staining for oestrogen receptors were the core biopsies. In addition, many of the excision specimens showed more prominent reactivity in HPB 2015, 17, 502-507 ª 2015 International Hepato-Pancreato-Biliary Association sections obtained from the periphery of the tissue. Formalin penetrates cellular tissue slowly at a rate of 1 mm per hour and therefore core biopsies of 1 mm in diameter will fix rapidly, whereas larger excision specimens will show a similar degree of fixation only at the edge. Given the staining patterns seen in the different specimen types, it seems likely that oestrogen receptor staining is influenced by fixation and that the best results are gained using tissue that fixes rapidly (Figs 1-4 ).
Human liver hepatocytes contain oestrogen receptors, which render the liver sensitive to hormonal manipulation. Porter et al.
12 studied oestrogen receptors in neoplastic and normal surrounding liver in three hepatic adenomas, one FNH and one normal liver sample. They showed that nuclear oestrogen receptor expression was much greater in adenoma and FNH compared with surrounding normal liver. This relative increase in nuclear oestrogen receptor binding capacity in adenoma and Focal nodular hyperplasia is a benign condition that can be accurately diagnosed using techniques such as magnetic resonance imaging (MRI). 23 Thus, over the course of more than a decade, in two major tertiary institutions, tumours from only 13 patients were available for testing. Despite the increasing accuracy of MRI in determining the diagnosis of FNH and its benign nature, some patients complain of persistent pain and symptoms caused by the FNH. The other reason for resection or biopsy is that atypical or inconclusive imaging findings may be suspicious for an adenoma or other neoplastic lesion. Interestingly, both male patients in this study showed oestrogen receptor expression in their FNH. Luciani et al. 24 studied clinical and imaging findings in 18 men with FNH and compared them with those in 216 women with FNH. They found that men were diagnosed at an older age than women, that the mean size of FNH was smaller in men than in women and that surgery was performed far more frequently in men than in women (72% versus 17%). These differences may relate to a larger proportion of atypical MRI findings and the greater risk for hepatocellular carcinoma in men. 24 There is conflicting evidence to support the hormonal basis to the pathophysiology of FNH, but, interestingly, there is evidence linking an increased risk for FNH with prolonged use of OCs. 25 An epidemiologic study of 23 women with FNH and 94 control subjects found contraceptive use was reported in 83% of those with FNH and 59% of controls, and identified a significant trend in increased risk for FNH with increased duration of OCP use [odds ratios (ORs): 1.62 in those using OCPs for <3 years and 4.48 in those using OCPs for >3 years in comparison with that in women who had never used OCPs]. 26 Heinemann et al. 27 performed two parallel case-control studies in a total of 51 patients with hepatocellular adenomas and 143 with FNH treated at 15 German liver centres between 1990 and 1997 and a comparison group of 240 population controls. There are data to support the suggestion that pregnancy does not increase the risk for significant growth or complications from FNH [30] [31] [32] and that pregnancy need not be discouraged in these patients. In a study conducted by Rifai et al. 30 in 20 patients with FNH monitored during pregnancy, three experienced tumour growth, seven showed a stable tumour size and 10 showed some degree of involution. In a study by Weimann et al., 32 conducted in 10 pregnant women, three of whom were pregnant twice, only one patient developed right upper quadrant pain in the course of the pregnancy and none showed an increase in tumour size. However, occasional case reports have described an increase in the size of FNH and heightened symptoms during pregnancy. 33, 34 Although FNH is traditionally associated with a very low to no incidence of complications, scattered reports suggest that complications of FNH such as rupture and bleeding do occur, although much less frequently than in the context of hepatic adenoma. [35] [36] [37] [38] [39] Albeit that the majority of patients with FNH are asymptomatic and are managed conservatively with observation, patients who develop abdominal pain, marked tumour enlargement or have atypical imaging findings may require surgery. 40, 41 On follow-up, up to 13% of patients who are under surveillance for FNH go on to develop protracted symptoms. 42 Hence, it is imperative that the surgeon who diagnoses the patient with FNH is able to give sound advice on OCP use. Several contemporary reports recommend the cessation of OCPs in patients with FNH.
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Conclusions
The present study demonstrates that the majority of FNH lesions and surrounding liver parenchyma express oestrogen receptors. This has not been demonstrated in previous studies. The current findings add additional uncertainty to the ongoing debate of the role of cessation of OCPs in women with FNH, thereby supporting the case for further study of this issue.
